首页> 外文会议>International Conference on Bioinformatics and Computational Biology >Fusion genes as putative microbial drug targets in H. pylori
【24h】

Fusion genes as putative microbial drug targets in H. pylori

机译:融合基因作为幽门螺杆菌的推定微生物药物靶标

获取原文

摘要

Fusion genes have been reported as a means of enabling the development of novel or enhanced functions. In this report, we analyzed fusion genes in the genomes of two Helicobacter pylori strains (26695 and J99) and identified 32 fusion genes that are present as neighbours in one strain (components) and are fused in the second (composite), and vice-versa. The mechanism for each case of gene fusion is explored. All the genes identified as fusion products in this analysis were reported as essential genes in this bacterium in the previously documented transposon mutagenesis of H. pylori strain G27. This observation suggests the potential of the products of fusion genes as putative microbial drug targets. These results underscore the utility of bacterial genomic sequence comparisons for understanding gene evolution and for in silico drug target identification in the post-genomic era.
机译:融合基因已被报告为能够开发新颖或增强功能的手段。在本报告中,我们分析了两个幽门螺杆菌菌株(26695和J99)的基因组中的融合基因,并鉴定了作为一个菌株(组分)中​​作为邻居存在的32个融合基因,并在第二(复合)和副中融合有关。探讨了对基因融合的每种情况的机制。在该分析中鉴定为融合产物的所有基因被报告为该细菌中的本细菌中的必需基因,以先前记载的H.幽门螺杆菌菌株G27。该观察结果表明融合基因产物的潜力作为推定的微生物药物靶标。这些结果强调了细菌基因组序列比较用于了解基因进化和在后基因组时代的硅药物靶标识的实用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号